Home » Thought Leadership » Research posters

Thought Leadership

Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 19 posts
ISPOR Asia-Pacific 2020 Research Poster from CBPartners
September 7, 2020 | Research posters

ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia

A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.

ISPOR Asia-Pacific 2020 Research Poster
September 7, 2020 | Research posters

ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations

A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.

ISPOR Asia-Pacific 2020 research poster from CBPartners
September 7, 2020 | Research posters

ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy

A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.

THE USE OF INTEGRATED DELIVERY NETWORKS [FINAL POSTER] WEB IMAGE
May 18, 2020 | Research posters

ISPOR Annual 2020: The Use of Integrated Delivery Networks as Pioneers for Manufacturer HEOR Program / Study Success

A research poster identifying the impact of utilizing Integrated Delivery Networks and their in-house resources in fulfilling HEOR program requirements.

RESUBMISSIONS WITH RWE CAN THEY HELP CHANGE YOUR BENEFIT RATING
May 18, 2020 | Research posters

ISPOR Annual 2020: Re-Submissions with RWE: Can They Help Change Your Benefit Rating?

A research poster that aims to understand the role of RWE in re-submissions and determine if this type of evidence can help to improve HTA outcomes when products are re-assessed by the Haute Autorité de Santé (HAS) in France and Gemeinsamer Bundesausschuss (G-BA) in Germany.